Activity

Filter

Cancel
Date Panel Item Activity
47 actions
Neurodegenerative disorders, adult onset v9.22 HSPB8 Luke Stuart changed review comment from: As reviewed by Oliver Ziff, HSPB8-related disease may present in adulthood or enter an adult lower motor neuron (LMN) disease or progressive muscular atrophy (PMA) diagnostic pathway because of overlapping clinical presentation (Putko et al. (2025) PMID 41426051)). NHS England review is ongoing to determine whether HSPB8 falls within the intended scope of the adult-onset neurodegenerative disorders panel, based on potential diagnostic utility rather than a definitive association with adult-onset neurodegeneration.; to: HSPB8 is associated with Charcot-Marie-Tooth disease, axonal, type 2L (OMIM:608673); Myopathy, myofibrillar, 13, with rimmed vacuoles (OMIM:621078); Neuronopathy, distal hereditary motor, autosomal dominant 2 (OMIM:158590) (accessed 10/2026).

As reviewed by Oliver Ziff, HSPB8-related disease may present in adulthood or enter an adult lower motor neuron (LMN) disease or progressive muscular atrophy (PMA) diagnostic pathway because of overlapping clinical presentation (Putko et al. (2025) PMID 41426051)). NHS England review is ongoing to determine whether HSPB8 falls within the intended scope of the adult-onset neurodegenerative disorders panel, based on potential diagnostic utility rather than a definitive association with adult-onset neurodegeneration.
Neurodegenerative disorders, adult onset v9.22 HSPB1 Luke Stuart changed review comment from: Variants in HSPB1 are a recurrent and established cause of distal Hereditary Motor Neuropathy (dHMN), and are associated with Charcot-Marie-Tooth disease, axonal, type 2F (CMT2F, OMIM:606595) and Neuronopathy, distal hereditary motor, autosomal dominant 3 (OMIM:608634) (accessed 10/2026). In a cohort of 301 individuals with CMT and 115 with distal hereditary motor neuropathy, a segregating HSPB1 missense variant was identified in a Russian CMT2F family, with four additional missense variants found across four distal-HMN families; mutant HSPB1 reduced neuronal-cell viability and disrupted neurofilament assembly (Evgrafov et al., (2004), PMID 15122254). As reviewed by Oliver Ziff, adult-onset HSPB1-related motor neuropathy may clinically resemble progressive muscular atrophy or motor neuron disease- in a natural history study of HSBP1 neuropathy, patients developed adult-onset progressive weakness, wasting and chronic denervation (Rossor et al. (2016), PMID 27816334.

Evidence for a direct association with classical ALS is limited and equivocal: Capponi et al. (2016), PMID 27492805, identified two variants in 247 patients with ALS, (c.570G>C, p.Gln190His and c.610dupG, p.Ala204GlyfsTer6); the latter impaired HSPB1 chaperone activity in vitro; Dierick et al. (2007), PMID 17623484, identified a functional promoter variant HSPB1 c.-217T>C in one patient reducing transcriptional activity by 50% and proposed as a potential risk modifier in motor neuron disease pathogenesis. Heilman et al. (2017), PMID 28797631, showed that neuropathy-associated HSPB1 variants p.Gly84Arg and p.Arg136Trp attenuated astrocytic HSPB1-mediated motor neuron protection.

Expert review is recommended to determine whether HSPB1 should be included in the adult onset neurodegenerative disorders panel to capture patients with HSPB1-related neuropathy who clinically mimic progressive muscular atrophy or motor neuron disease, rather than as an established cause of motor neuron disease.; to: Variants in HSPB1 are a recurrent and established cause of distal Hereditary Motor Neuropathy (dHMN), and are associated with Charcot-Marie-Tooth disease, axonal, type 2F (CMT2F, OMIM:606595) and Neuronopathy, distal hereditary motor, autosomal dominant 3 (OMIM:608634) (accessed 10/2026). In a cohort of 301 individuals with CMT and 115 with distal hereditary motor neuropathy, a segregating HSPB1 missense variant was identified in a Russian CMT2F family, with four additional missense variants found across four distal-HMN families; mutant HSPB1 reduced neuronal-cell viability and disrupted neurofilament assembly (Evgrafov et al., (2004), PMID 15122254). As reviewed by Oliver Ziff, adult-onset HSPB1-related motor neuropathy may clinically resemble progressive muscular atrophy or motor neuron disease- in a natural history study of HSBP1 neuropathy, patients developed adult-onset progressive weakness, wasting and chronic denervation (Rossor et al. (2016), PMID 27816334.

Evidence for a direct association with classical ALS is limited and equivocal: Capponi et al. (2016), PMID 27492805, identified two variants in 247 patients with ALS, (c.570G>C, p.Gln190His and c.610dupG, p.Ala204GlyfsTer6); the latter impaired HSPB1 chaperone activity in vitro; Dierick et al. (2007), PMID 17623484, identified a functional promoter variant HSPB1 c.-217T>C in one patient reducing transcriptional activity by 50% and proposed as a potential risk modifier in motor neuron disease pathogenesis. Heilman et al. (2017), PMID 28797631, showed that neuropathy-associated HSPB1 variants p.Gly84Arg and p.Arg136Trp attenuated astrocytic HSPB1-mediated motor neuron protection.

NHS England review is ongoing to determine whether HSPB1 should be included in the adult onset neurodegenerative disorders panel to capture patients with HSPB1-related neuropathy who clinically mimic progressive muscular atrophy or motor neuron disease, rather than as an established cause of motor neuron disease.
Neurodegenerative disorders, adult onset v9.22 SIGMAR1 Luke Stuart changed review comment from: SIGMAR1 is provisionally associated with autosomal recessive Amyotrophic lateral sclerosis 16, juvenile (OMIM:614373) and Neuronopathy, distal hereditary motor, autosomal recessive 2 (OMIM:605726) (accessed 10/2026). Multiple patients with biallelic variants have been identified, and disease onset is typically in the first decade (Kalita et al. (2025), PMID 41334667; Al-Saif et al. (2011), PMID 21842496, Horga et al. (2016) PMID 27629094). Disruption of Sigmar1 in the mouse leads to locomotor deficit (Bernard-Marissal et al. (2015), PMID 25678561).

Biallelic SIGMAR1 variants typically cause a phenotypic spectrum encompassing juvenile ALS16 and distal hereditary motor neuropathy with pyramidal signs. Recent evidence supports a spectrum of SIGMAR1-related motor neuropathy, with the slowly progressive, distal-predominant phenotype generally favouring dHMN over classical ALS (Yu et al. (2025), PMID 40309037; Kalita et al. (2025), PMID 41334667)).

Adult presentation is documented in isolated cases. Ma et al. (2020), PMID 32600828 reported onset at 34 years in a patient with compound-heterozygous c.247T>C and c.545T>C variants who was referred to an ALS clinic with distal weakness and hyperreflexia; the authors classified the phenotype as dHMN mimicking ALS. An additional Japanese patient developed ALS at 80 years with compound-heterozygous missense variants, though notably, one of the variants (p.R208W) has an allele frequency of 2.9% in East Asians via gnomad v4 and 64 homozygotes across all populations (Izumi et al. (2018), PMID 30311446). Evidence implicating SIGMAR1 in typical adult-onset ALS or ALS–FTD remains disputed (Pickering-Brown et al. (2015), PMID 26088964). SIGMAR1 c.672*51G>T was identified in 3 families with ALS-FTD, though later studies found one of the families also to harbored a C9ORF72 expansion (Luty et al. (2010), PMID 21031579.

As reviewed by Oliver Ziff, despite typical childhood onset, SIGMAR1-related disease can thus present in adulthood or enter an adult ALS/LMN pathway because of overlapping clinical presentation. Expert review is therefore warranted to determine whether SIGMAR1 should be included on the adult-onset neurodegenerative disorders panel in the context of diagnostic utility, rather than in relation to a definitive association between SIGMAR1 and adult-onset neurodegeneration.; to: SIGMAR1 is provisionally associated with autosomal recessive Amyotrophic lateral sclerosis 16, juvenile (OMIM:614373) and Neuronopathy, distal hereditary motor, autosomal recessive 2 (OMIM:605726) (accessed 10/2026). Multiple patients with biallelic variants have been identified, and disease onset is typically in the first decade (Kalita et al. (2025), PMID 41334667; Al-Saif et al. (2011), PMID 21842496, Horga et al. (2016) PMID 27629094). Disruption of Sigmar1 in the mouse leads to locomotor deficit (Bernard-Marissal et al. (2015), PMID 25678561).

Biallelic SIGMAR1 variants typically cause a phenotypic spectrum encompassing juvenile ALS16 and distal hereditary motor neuropathy with pyramidal signs. Recent evidence supports a spectrum of SIGMAR1-related motor neuropathy, with the slowly progressive, distal-predominant phenotype generally favouring dHMN over classical ALS (Yu et al. (2025), PMID 40309037; Kalita et al. (2025), PMID 41334667)).

Adult presentation is documented in isolated cases. Ma et al. (2020), PMID 32600828 reported onset at 34 years in a patient with compound-heterozygous c.247T>C and c.545T>C variants who was referred to an ALS clinic with distal weakness and hyperreflexia; the authors classified the phenotype as dHMN mimicking ALS. An additional Japanese patient developed ALS at 80 years with compound-heterozygous missense variants, though notably, one of the variants (p.R208W) has an allele frequency of 2.9% in East Asians via gnomad v4 and 64 homozygotes across all populations (Izumi et al. (2018), PMID 30311446). Evidence implicating SIGMAR1 in typical adult-onset ALS or ALS–FTD remains disputed (Pickering-Brown et al. (2015), PMID 26088964). SIGMAR1 c.672*51G>T was identified in 3 families with ALS-FTD, though later studies found one of the families also to harbored a C9ORF72 expansion (Luty et al. (2010), PMID 21031579.

As reviewed by Oliver Ziff, despite typical childhood onset, SIGMAR1-related disease can thus present in adulthood or enter an adult ALS/LMN pathway because of overlapping clinical presentation. NHS England review is ongoing to determine whether SIGMAR1 falls within the intended scope of the adult-onset neurodegenerative disorders panel, based on potential diagnostic utility rather than a definitive association with adult-onset neurodegeneration.
Neurodegenerative disorders, adult onset v7.14 SGIP1 Arina Puzriakova Added comment: Comment on publications: PMID:39332416 was identified by the Genomics England Applied Machine Learning (ML) team in a Biocuration-ML project for identifying new gene-disease associations using Natural Language Processing (NLP) and Generative AI techniques.
Neurodegenerative disorders, adult onset v7.10 POLG Sarah Leigh Added comment: Comment on publications: PMID: 39498811 was identified by the Genomics England Applied Machine Learning (ML) team in a Biocuration-ML project for identifying new gene-disease associations using Natural Language Processing (NLP) and Generative AI techniques.
Neurodegenerative disorders, adult onset v3.49 GLA Arina Puzriakova Tag Q1_23_promote_green was removed from gene: GLA.
Neurodegenerative disorders, adult onset v3.49 GLA Arina Puzriakova reviewed gene: GLA: Rating: GREEN; Mode of pathogenicity: ; Publications: ; Phenotypes: ; Mode of inheritance:
Neurodegenerative disorders, adult onset v3.48 GLA Arina Puzriakova Source NHS GMS was added to GLA.
Source Expert Review Green was added to GLA.
Rating Changed from Amber List (moderate evidence) to Green List (high evidence)
Neurodegenerative disorders, adult onset v3.36 GLA Achchuthan Shanmugasundram Tag Q1_23_promote_green tag was added to gene: GLA.
Neurodegenerative disorders, adult onset v3.19 GLA Achchuthan Shanmugasundram Phenotypes for gene: GLA were changed from to Fabry disease, OMIM:301500
Neurodegenerative disorders, adult onset v3.18 GLA Achchuthan Shanmugasundram Mode of inheritance for gene: GLA was changed from to X-LINKED: hemizygous mutation in males, monoallelic mutations in females may cause disease (may be less severe, later onset than males)
Neurodegenerative disorders, adult onset v3.17 GLA Achchuthan Shanmugasundram Classified gene: GLA as Amber List (moderate evidence)
Neurodegenerative disorders, adult onset v3.17 GLA Achchuthan Shanmugasundram Gene: gla has been classified as Amber List (Moderate Evidence).
Neurodegenerative disorders, adult onset v3.16 GLA Achchuthan Shanmugasundram reviewed gene: GLA: Rating: GREEN; Mode of pathogenicity: None; Publications: ; Phenotypes: Fabry disease, OMIM:301500; Mode of inheritance: X-LINKED: hemizygous mutation in males, monoallelic mutations in females may cause disease (may be less severe, later onset than males)
Neurodegenerative disorders, adult onset v3.4 GLA Eleanor Williams reviewed gene: GLA: Rating: ; Mode of pathogenicity: ; Publications: ; Phenotypes: Fabry disease; Mode of inheritance: X-LINKED: hemizygous mutation in males, monoallelic mutations in females may cause disease (may be less severe, later onset than males)
Neurodegenerative disorders, adult onset v3.3 GLA Eleanor Williams gene: GLA was added
gene: GLA was added to Neurodegenerative disorders - adult onset. Sources: Expert list
Mode of inheritance for gene: GLA was set to
Neurodegenerative disorders, adult onset v2.201 FIG4 Sarah Leigh changed review comment from: In with respect to Ian Berry's proposed demotion of FIG4, after reviewing PMID:19118816. Helen Brittain (Genomics England Clinical Fellow) has suggested the rating of this gene should be considered by TEWG oversight committee, as there is a lack of evidence for ALS.; to: Q4_21_expert_review tag has been added to this gene. Helen Brittain (Genomics England Clinical Fellow) has suggested that the rating of this gene should be considered by TEWG oversight committee, in response to Ian Berry's proposed demotion of FIG4, after reviewing PMID:19118816, which shows a lack of evidence for ALS.
Neurodegenerative disorders, adult onset v2.201 FIG4 Sarah Leigh edited their review of gene: FIG4: Added comment: In with respect to Ian Berry's proposed demotion of FIG4, after reviewing PMID:19118816. Helen Brittain (Genomics England Clinical Fellow) has suggested the rating of this gene should be considered by TEWG oversight committee, as there is a lack of evidence for ALS.; Changed rating: AMBER
Neurodegenerative disorders, adult onset v2.109 OPTN Ivone Leong Phenotypes for gene: OPTN were changed from Glaucoma 1, open angle, E, 137760; Amyotrophic Lateral Sclerosis, Recessive to Amyotrophic lateral sclerosis 12 with or without frontotemporal dementia, OMIM:613435
Neurodegenerative disorders, adult onset v2.38 HTT_CAG Arina Puzriakova commented on STR: HTT_CAG: Tagged 'for-review' to highlight the recent review by Helen Brittain (Genomics England Clinical Team) indicating that exclusion of this STR may increase risk of missed diagnoses. HTT_CAG was removed from this panel in October 2020 at request of the GMS Specialist Test Group.
Neurodegenerative disorders, adult onset v2.30 PPP2R2B_CAG Arina Puzriakova Added comment: Comment on list classification: Downgraded from Green to Amber as this STR was not listed on the recent GMS STRs document supplied by Jane Deller (NHS England) on behalf of GLHs for the GMS Neurology Test Group
Neurodegenerative disorders, adult onset v2.29 NOP56_GGCCTG Arina Puzriakova Added comment: Comment on list classification: Downgraded from Green to Amber as this STR was not listed on the recent GMS STRs document supplied by Jane Deller (NHS England) on behalf of GLHs for the GMS Neurology Test Group
Neurodegenerative disorders, adult onset v2.28 FXN_GAA Arina Puzriakova Added comment: Comment on list classification: Downgraded from Green to Amber as this STR was not listed on the recent GMS STRs document supplied by Jane Deller (NHS England) on behalf of GLHs for the GMS Neurology Test Group
Neurodegenerative disorders, adult onset v2.27 CSTB_CCCCGCCCCGCG Arina Puzriakova Added comment: Comment on list classification: Downgraded from Green to Amber as this STR was not listed on the recent GMS STRs document supplied by Jane Deller (NHS England) on behalf of GLHs for the GMS Neurology Test Group
Neurodegenerative disorders, adult onset v2.26 CACNA1A_CAG Arina Puzriakova Added comment: Comment on list classification: Downgraded from Green to Amber as this STR was not listed on the recent GMS STRs document supplied by Jane Deller (NHS England) on behalf of GLHs for the GMS Neurology Test Group
Neurodegenerative disorders, adult onset v2.25 ATXN7_CAG Arina Puzriakova Added comment: Comment on list classification: Downgraded from Green to Amber as this STR was not listed on the recent GMS STRs document supplied by Jane Deller (NHS England) on behalf of GLHs for the GMS Neurology Test Group
Neurodegenerative disorders, adult onset v2.24 ATXN3_CAG Arina Puzriakova Added comment: Comment on list classification: Downgraded from Green to Amber as this STR was not listed on the recent GMS STRs document supplied by Jane Deller (NHS England) on behalf of GLHs for the GMS Neurology Test Group
Neurodegenerative disorders, adult onset v2.23 ATXN2_CAG Arina Puzriakova Added comment: Comment on list classification: Downgraded from Green to Amber as this STR was not listed on the recent GMS STRs document supplied by Jane Deller (NHS England) on behalf of GLHs for the GMS Neurology Test Group
Neurodegenerative disorders, adult onset v2.22 ATXN1_CAG Arina Puzriakova Added comment: Comment on list classification: Downgraded from Green to Amber as this STR was not listed on the recent GMS STRs document supplied by Jane Deller (NHS England) on behalf of GLHs for the GMS Neurology Test Group
Neurodegenerative disorders, adult onset v2.21 ATXN10_ATTCT Arina Puzriakova Added comment: Comment on list classification: Downgraded from Green to Amber as this STR was not listed on the recent GMS STRs document supplied by Jane Deller (NHS England) on behalf of GLHs for the GMS Neurology Test Group
Neurodegenerative disorders, adult onset v2.12 ISCA-37478-Gain Arina Puzriakova changed review comment from: Comment on list classification: This region has been removed from the panel at the request of NHS England following discussion at a Rare Disease workshop.; to: Comment on list classification: This region has been removed from the panel at the request of NHS England following discussion at a Rare Disease workshop. Removed as testing for this region is not achievable using currently available methodology.
Neurodegenerative disorders, adult onset v2.12 ISCA-37468-Loss Arina Puzriakova changed review comment from: Comment on list classification: This region has been removed from the panel at the request of NHS England following discussion at a Rare Disease workshop.; to: Comment on list classification: This region has been removed from the panel at the request of NHS England following discussion at a Rare Disease workshop. Removed as testing for this region is not achievable using currently available methodology.
Neurodegenerative disorders, adult onset v2.12 ISCA-37404-Loss Arina Puzriakova changed review comment from: Comment on list classification: This region has been removed from the panel at the request of NHS England following discussion at a Rare Disease workshop.; to: Comment on list classification: This region has been removed from the panel at the request of NHS England following discussion at a Rare Disease workshop. Removed as testing for this region is not achievable using currently available methodology.
Neurodegenerative disorders, adult onset v2.12 ISCA-37478-Loss Arina Puzriakova changed review comment from: Comment on list classification: This region has been removed from the panel at the request of NHS England following discussion at a Rare Disease workshop.; to: Comment on list classification: This region has been removed from the panel at the request of NHS England following discussion at a Rare Disease workshop. Removed as testing for this region is not achievable using currently available methodology.
Neurodegenerative disorders, adult onset v2.8 ISCA-37478-Loss Arina Puzriakova Added comment: Comment on list classification: This region has been removed from the panel at the request of NHS England following discussion at a Rare Disease workshop.
Neurodegenerative disorders, adult onset v2.7 ISCA-37478-Gain Arina Puzriakova Added comment: Comment on list classification: This region has been removed from the panel at the request of NHS England following discussion at a Rare Disease workshop.
Neurodegenerative disorders, adult onset v2.6 ISCA-37404-Loss Arina Puzriakova Added comment: Comment on list classification: This region has been removed from the panel at the request of NHS England following discussion at a Rare Disease workshop.
Neurodegenerative disorders, adult onset v2.5 ISCA-37468-Loss Arina Puzriakova Added comment: Comment on list classification: This region has been removed from the panel at the request of NHS England following discussion at a Rare Disease workshop.
Neurodegenerative disorders, adult onset v1.99 OPTN Tracy Lester reviewed gene: OPTN: Rating: GREEN; Mode of pathogenicity: ; Publications: ; Phenotypes: Glaucoma 1, open angle, E, 137760, Amyotrophic Lateral Sclerosis, Recessive; Mode of inheritance: BOTH monoallelic and biallelic, autosomal or pseudoautosomal
Neurodegenerative disorders, adult onset v1.78 CHMP2B Louise Daugherty commented on gene: CHMP2B: Comment: - PMID: 20352044 conclude that in a population drawn from North of England pathogenic CHMP2B mutations are found in approximately 1% of cases of ALS and 10% of those with lower motor neuron predominant ALS. We provide a body of evidence indicating the likely pathogenicity of the reported gene alterations. However, absolute confirmation of pathogenicity requires further evidence, including documentation of familial transmission in ALS pedigrees which might be most fruitfully explored in cases with a LMN predominant phenotype.
Neurodegenerative disorders, adult onset v1.78 CHMP2B Louise Daugherty changed review comment from: Review and rating submitted byJames Polke (North Bristol NHS Trust), unless specified in the review comment, on behalf of London North GLH for GMS Neurology specialist test group. Comment: - We conclude that in a population drawn from North of England pathogenic CHMP2B mutations are found in approximately 1% of cases of ALS and 10% of those with lower motor neuron predominant ALS. We provide a body of evidence indicating the likely pathogenicity of the reported gene alterations. However, absolute confirmation of pathogenicity requires further evidence, including documentation of familial transmission in ALS pedigrees which might be most fruitfully explored in cases with a LMN predominant phenotype.; to: Review and rating submitted byJames Polke (North Bristol NHS Trust), unless specified in the review comment, on behalf of London North GLH for GMS Neurology specialist test group.
Neurodegenerative disorders, adult onset v1.78 CHMP2B Louise Daugherty changed review comment from: Review and rating submitted byJames Polke (North Bristol NHS Trust), unless specified in the review comment, on behalf of London North GLH for GMS Neurology specialist test group.; to: Review and rating submitted byJames Polke (North Bristol NHS Trust), unless specified in the review comment, on behalf of London North GLH for GMS Neurology specialist test group. Comment: - We conclude that in a population drawn from North of England pathogenic CHMP2B mutations are found in approximately 1% of cases of ALS and 10% of those with lower motor neuron predominant ALS. We provide a body of evidence indicating the likely pathogenicity of the reported gene alterations. However, absolute confirmation of pathogenicity requires further evidence, including documentation of familial transmission in ALS pedigrees which might be most fruitfully explored in cases with a LMN predominant phenotype.
Neurodegenerative disorders, adult onset v1.78 CHMP2B Louise Daugherty Publications for gene: CHMP2B were set to PMID: 20352044 - We conclude that in a population drawn from North of England pathogenic CHMP2B mutations are found in approximately 1% of cases of ALS and 10% of those with lower motor neuron predominant ALS. We provide a body of evidence indicating the likely pathogenicity of the reported gene alterations. However, absolute confirmation of pathogenicity requires further evidence, including documentation of familial transmission in ALS pedigrees which might be most fruitfully explored in cases with a LMN predominant phenotype.
Neurodegenerative disorders, adult onset v1.72 OPTN Nick Beauchamp reviewed gene: OPTN: Rating: GREEN; Mode of pathogenicity: ; Publications: 20428114, 23889540; Phenotypes: Glaucoma 1, open angle, E, 137760, Amyotrophic Lateral Sclerosis, Recessive; Mode of inheritance: BOTH monoallelic and biallelic, autosomal or pseudoautosomal; Current diagnostic: yes
Neurodegenerative disorders, adult onset v1.62 CTSF Louise Daugherty Added comment: Comment on list classification: New gene added from curation of Undiagnosed metabolic disorders panel and recommended by Genomics England clinical team to add to the Neurodegenerative disorders - adult onset panel. This is reported with onset in adulthood (youngest 20 yrs, oldest 35 yrs) with neurological features and cognitive decline.
Neurodegenerative disorders, adult onset v0.2 OPTN Rebecca Foulger gene: OPTN was added
gene: OPTN was added to Neurodegenerative disorders - adult onset. Sources: Expert Review Green
Mode of inheritance for gene: OPTN was set to BOTH monoallelic and biallelic, autosomal or pseudoautosomal
Publications for gene: OPTN were set to PMID: 25943890; (iii) It is not uncommon for multiple ALS-causing mutations to occur in the same patient; (ii) optineurin protein is present in a subset of the extramotor inclusions of C9ORF72-ALS; PMID: 26203661; PMID: 25859013 - functional evidence; PMID: 25681989; PMID: 26303227 We conclude that: (i) OPTN mutations are associated with ALS; PMID: 26503823; PMID: 26566915 - Here, we report a Chinese family spanning three generations with ALS8 caused by the same VAPB-P56S mutation detected in these cohorts, but which in its initial manifestation displays different features. We also detected a R545Q variant of optineurin (OPTN) in this family and which was previously considered a pathogenic mutation. However, our analysis showed that OPTN-R545Q is benign and that VAPB-P56S accounts for the phenotype.; and (iv) studies of optineurin are likely to provide useful dataregarding the pathophysiology of ALS and neurodegeneration.
Phenotypes for gene: OPTN were set to Glaucoma 1, open angle, E, 137760; Amyotrophic Lateral Sclerosis, Recessive
Neurodegenerative disorders, adult onset v0.2 CHMP2B Rebecca Foulger gene: CHMP2B was added
gene: CHMP2B was added to Neurodegenerative disorders - adult onset. Sources: Expert Review Green
Mode of inheritance for gene: CHMP2B was set to MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown
Publications for gene: CHMP2B were set to PMID: 20352044 - We conclude that in a population drawn from North of England pathogenic CHMP2B mutations are found in approximately 1% of cases of ALS and 10% of those with lower motor neuron predominant ALS. We provide a body of evidence indicating the likely pathogenicity of the reported gene alterations. However, absolute confirmation of pathogenicity requires further evidence, including documentation of familial transmission in ALS pedigrees which might be most fruitfully explored in cases with a LMN predominant phenotype.
Phenotypes for gene: CHMP2B were set to Dementia, familial, nonspecific, 600795Amyotrophic lateral sclerosis 17, 614696; Frontotemporal Dementia